Ithar Gataa's research while affiliated with Paris Descartes University and other places

Publications (15)

Article
Full-text available
Background: Nivolumab improved patients' survival in metastatic renal cell carcinoma (mRCC). We aimed to evaluate resting energy expenditure (REE) (i.e., patients' basal metabolism) to predict efficacy. Methods: We conducted a monocentric, observational study of mRCC patients receiving nivolumab between October 2015 and May 2020. REE was measure...
Article
Full-text available
Background The risk of drug–drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment.Patients and methodsWe perf...
Article
Cancer patients are a highly vulnerable group in the COVID-19 pandemic and it has been necessary for oncology units to adapt to this unexpected situation. We present our management of outpatients with cancer during the pandemic. We applied two major adaptations: extending the intervals between injections for maintenance therapy and protocol adaptat...
Preprint
Full-text available
Background: The risk of drug drug interactions (DDI) has become a major issue in cancer patient care. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency of DDI with antitumor treatments, identify the risk factors for DDI and evaluate the impact of a pharmacist evaluation before anticancer treatment. Patients and Method...
Conference Paper
Background: Neoadjuvant chemotherapy with intercalated surgery is the standard of care for resectable high-grade bone sarcoma (BS) but identification of biomarkers for chemosensitivity prediction is still needed. Insulin-like Growth Factor (IGF) pathway was first linked with sarcoma biology approximately 30 years ago (El-Brady OM, 1990). Methods: W...
Article
e22506 Background: Neoadjuvant chemotherapy with intercalated surgery is the standard of care for resectable high-grade bone sarcoma (BS) but identification of biomarkers for chemosensitivity prediction is still needed. Methods: We recruited 121 pts with new primary localized or metastatic BS, measured fasting blood glucose and insulin, body mass i...
Article
Introduction et but de l’étude La cachexie constitue une cause majeure de décès en cancérologie et s’accompagne d’une toxicité accrue des traitements anti-tumoraux. L’hypermétabolisme est fréquent chez les patients atteints de cancer et contribue à l’évolution vers la cachexie. Nous avons étudié la relation entre la dépense énergétique de repos (DE...
Article
Background: Although the efficiency of oxaliplatin in patients with advanced ovarian cancer has been demonstrated, it is not commonly used. In cells, oxaliplatin is metabolized by the enzymes belonging to the glutathione-S-transferase (GST) family. Case: A 55-year-old woman with advanced ovarian cancer received 6 cycles of paclitaxel and carbopl...

Citations

... There are also key papers looking at the service response in oncology, both in an acute setting as well as cancer outpatient care. 3,4 Peritoneal dialysis patients are another vulnerable group who have been less studied. Balson and Baharani report on a novel patient-reported questionnaire tool to document patient experience. ...
... Education level was university degree in 19%, high school diploma in 46.5%. The mean age of minors was 14 years [8][9][10][11][12][13][14][15][16][17][18] [ Table 1]. ...
... The role of GSTM1 null genotype as a susceptibility factor for various carcinoma is conflicting, although a large meta-analysis comprising 198 studies revealed an association of lung cancer to GSTM1 null genotype 48 . Other studies have suggested that GSTM1 null genotype is associated with pathogenesis of chronic obstructive pulmonary disease 49 , or increased likelihood of toxicity of cyclophosphamide 50 and oxaliplatin 51 . Our results show a high prevalence of putative "at risk" null genotype (59%). ...